FULGENT GENETICS, INC. Form 8-K (Sept. 24, 2022)

Summary

FULGENT GENETICS, INC. Form 8-K with a September 24, 2022 date of earliest event reported, filed under Item 5.02, Departure of Directors or Certain Officers. On September 24, 2022, John Bolger notified the Board of Directors of his decision to resign from the Board. He resigned as Chair of the Audit Committee and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee, effective September 24, 2022. The report states that his decision was not due to any disagreement with the company on any matter relating to its operations, policies or practices. Paul Kim, Chief Financial Officer, signed on September 29, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

!

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 24, 2022

FULGENT GENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware | 001-37894 | 81-2621304
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
4978 Santa Anita Avenue Temple City , California | 91780
(Address of Principal Executive Offices) | (Zip Code)

( 626 ) 350-0537

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.0001 per share | FLGT | The Nasdaq Stock Market (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 24, 2022, John Bolger notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board. Mr. Bolger resigned as the Chair of the Audit Committee and member of the Compensation Committee and Nominating and Corporate Governance Committee, effective as of September 24, 2022. Mr. Bolger’s decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 29, 2022 | FULGENT GENETICS, INC.
By: | /s/ Paul Kim
Name: | Paul Kim
Title: | Chief Financial Officer

File and source

File

SEC_FLGT_8-K_filed2022-09-29_0000950170-22-019049.htm

Size

49,647 bytes

SHA-256

dd01c484e71024f296a9c7a461b2ea1a9f2b5dda7ee50ffdb48e7fd3b33fb0a4

Our copy

SEC_FLGT_8-K_filed2022-09-29_0000950170-22-019049.htm

Original

www.sec.gov